99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

Kılçar, Ayfer Yurt; Tekin, Volkan; Müftüler, Fazilet Zümrüt Biber; Medine, E. Ilker

doi:10.1007/s10967-015-4284-1

Cited by 12 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies found that plumbagin potently exhibited an anticancer effect against estrogen receptor (ER)-positive cell lines. Furthermore, plumbagin had a high specificity for ERs that were highly expressed in MCF-7 cells, but a low specificity for MDA-MB-231 cells [ 42 ]. Therefore, in this investigation, we aim to investigate the impact of plumbagin on the ER-positive MCF-7 cell line associated with HIF-1α.…”

Section: Discussionmentioning

confidence: 99%

Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition

et al. 2022

View full text Add to dashboard Cite

Hypoxia-inducible factor-1α (HIF-1α) is a major transcriptional regulator that plays a crucial role in the hypoxic response of rapidly growing tumors. Overexpression of HIF-1α has been associated with breast cancer metastasis and poor clinical prognosis. Plumbagin, the main phytochemical from Plumbago indica, exerts anticancer effects via multiple mechanisms. However, its precise mechanisms on breast cancer cells under hypoxic conditions has never been investigated. This study aims to examine the anticancer effect of plumbagin on MCF-7 cell viability, transcriptional activity, and protein expression of HIF-1α under normoxia and hypoxia-mimicking conditions, as well as reveal the underlying signaling pathways. The results demonstrate that plumbagin decreased MCF-7 cell viability under normoxic conditions, and a greater extent of reduction was observed upon exposure to hypoxic conditions induced by cobalt chloride (CoCl2). Mechanistically, MCF-7 cells upregulated the expression of HIF-1α protein, mRNA, and the VEGF target gene under CoCl2-induced hypoxia, which were abolished by plumbagin treatment. In addition, inhibition of HIF-1α and its downstream targets did not affect the signaling transduction of the PI3K/Akt/mTOR pathway under hypoxic state. This study provides mechanistic insight into the anticancer activity of plumbagin in breast cancer cells under hypoxic conditions by abolishing HIF-1α at transcription and post-translational modifications.

show abstract

Section: Discussionmentioning

confidence: 99%

Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a study, Plumbagin (PL) that is a plant origin product, has various biological activities like anticancer activity and specificity to estrogen receptor (ER), was used. Yurt Kilcar et al radiolabeled PL and investigated in vitro studies on ER + and ERadeno carcinoma cells [31]. Additionally, poly (D,L-lactide)-coglycolide (PLGA) encapsulation was carried out to reduce toxicity of PL and encapsulation effect was investigated.…”

Section: Wang Et Al Designed and Synthesized [ 111mentioning

confidence: 99%

“…So, the authors conclude the PL has a favorable potential on ER specific breast cancer diagnosis and PLGA encapsulation has a positive effect on this potential increasing its ER specificity. Therefore, within the naturally occurring naphthoquinones PL, as a promising anticancer agent will necessitate further deep investigation for a probable use for diagnosis of ER+ breast cancer.PL as a promising agent for the diagnosis of ER + breast cancer [31].…”

Section: Wang Et Al Designed and Synthesized [ 111mentioning

confidence: 99%

Estimating Binding Capability of Radiopharmaceuticals by Cell Culture Studies

Özdemir¹,

Ekinci²,

Gündoğdu³

et al. 2016

Int J Med Nano Res

View full text Add to dashboard Cite

show abstract

Plumbagin and Its Role in Chronic Diseases

Panichayupakaranant

Ahmad

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a plant-derived naphthoquinones obtained mainly from three families, including Plumbaginaceae, Droseraceae, and Ebenaceae. Plumbagin has exhibited its potential therapeutic benefits on numerous chronic diseases, i.e., breast cancer, non-small cell lung cancer, melanoma, ovarian, squamous cell carcinomas, pancreatic cancer, and prostate cancer. In addition, its anti-inflammatory and antimicrobial activities as well as control of diabetes and cardiovascular diseases have been reported. Thus, plumbagin is a promising agent for development as a new drug for the treatment or control of chronic diseases. Studies on controlled drug release or drug delivery systems have been involved for improvement of its therapeutic efficacy as well as for the reduction of its toxicity. However, most of the recent research information is from in vitro and in vivo studies. Further clinical studies are therefore required for its developments and applications as a novel drug used to treat chronic diseases.

show abstract

99mTc labeled plumbagin: estrogen receptor dependent examination against breast cancer cells and comparison with PLGA encapsulated form

Cited by 12 publications

References 37 publications

Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition

Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition

Estimating Binding Capability of Radiopharmaceuticals by Cell Culture Studies

Plumbagin and Its Role in Chronic Diseases

Contact Info

Product

Resources

About